Skip to main content

Otsuka prices depression digital therapeutic to make it widely accessible, says it’ll lose money

By STAT News  
   August 14, 2024

Otsuka Pharmaceutical has started selling Rejoyn, its Food and Drug Administration cleared prescription app that treats the symptoms of major depressive disorder. And it’s hitting the market at a low price that Otsuka hopes will entice many people to give it a try.

Full story


Get the latest on healthcare leadership in your inbox.